Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy

Clinical Infectious Diseases

Volumn 38, Issue 10, 2004, Pages 1485-1489

  Goldman, Mitchell ^a,k   Zackin, Robert ^b   Fichtenbaum, Carl J ^c   Skiest, Daniel J ^d   Koletar, Susan L ^e   Hafner, Richard ^f   Wheat, L Joseph ^a,i   Nyangweso, Peter M ^b   Yiannoutsos, Constantin T ^a,b   Schnizlein Bick, Carol T ^a   Owens, Susan ^g   Aberg, Judith A ^h,j  

^a INDIANA UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MIRAVISTA DIAGNOSTICS   (United States)

^j NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; FLUCONAZOLE; FUNGUS ANTIGEN; ITRACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNGAL CELL CULTURE; HISTOPLASMA; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; URINE;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HISTOPLASMA; HISTOPLASMOSIS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 2442704003     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/420749     Document Type: Article

References (20)

1. Wheat J. Histoplasmosis in the acquired immunodeficiency syndrome. Curr Top Med Mycol 1996; 7:7-18.
2. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine 1990; 69:361-74.
3. Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. The National Institute of Allergy and Infectious Diseases Clinical Trials and Mycoses Study Group Collaborators. Ann Intern Med 1993; 118:610-6.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [comment]. N Engl J Med 1998; 338:853-60.
5. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study [comment]. JAMA 1999; 282:2220-6.
6. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98 [comment]. N Engl J Med 2001; 344:159-67.
7. 6/L. AIDS 2001; 15:1509-15.
8. + cell count: a randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 2000; 133:493-503.
9. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 2000; 342:1085-92.
10. Shafran SD, Mashinter LD, Phillips P, et al. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy [summary for patients in Ann Intern Med 2002; 137:I48]. Ann Intern Med 2002; 137:734-7.
11. Aberg JA, Williams PL, Liu T, et al. A study of discontinuing maintenance therapy in human immunodeficiency virus - infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis 2003; 187:1046-52. [Erratum appears in J Infect Dis 2003; 187:1346.]
12. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002; 185: 1179-82.
13. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003; 36:1329-31.
14. Martinez E, Garcia-Viejo MA, Marcos MA, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14:2615-7.
15. Rollot F, Bossi P, Tubiana R, et al. Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy. AIDS 2001; 15:1448-9.
16. Jouan M, Saves M, Tubiana R, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2001; 15:23-31.
17. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy [comment]. J Infect Dis 1998; 177:1182-7.
18. Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986; 314:83-8.
19. Wheat LJ, Connolly-Stringfield P, Blair R, Connolly K, Garringer T, Katz BP. Histoplasmosis relapse in patients with AIDS: detection using Histoplasma capsulatum variety capsulatum antigen levels. Ann Intern Med 1991; 115:936-41.
20. Sued O, Abusamra O, Helou S, et al. Discontinuation of maintenance therapy for disseminated histoplasmosis: a study of 39 patients [abstract ThPeC7476]. In: Program and abstracts of the 14th International AIDS Conference. Barcelona, Spain: International AIDS Society, 2002.